AZD3632
/ AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 29, 2025
MOMENTUM: Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
(clinicaltrials.gov)
- P1/2 | N=84 | Not yet recruiting | Sponsor: AstraZeneca | Trial completion date: Jun 2029 ➔ Feb 2029 | Trial primary completion date: Jun 2029 ➔ Feb 2029
Monotherapy • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
September 04, 2025
MOMENTUM: Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
(clinicaltrials.gov)
- P1/2 | N=84 | Not yet recruiting | Sponsor: AstraZeneca
Monotherapy • New P1/2 trial • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
1 to 2
Of
2
Go to page
1